AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Hanover Bank Launches Radio & Digital Audio Campaign to Strengthen Community Ties and Growth Strategy
ByAinvest
Thursday, Aug 7, 2025 8:02 am ET1min read
Ascentage Pharma will report its 2025 six-month interim results and provide a corporate update on August 20, 2025. The company will host a Chinese language investor webcast at 9:00 pm EDT and an English language webcast at 8:00 am EDT on August 21, 2025. Ascentage Pharma is a global biopharmaceutical company developing novel therapies for cancer. Its first approved product, Olverembatinib, is a third-generation BCR-ABL1 inhibitor, while its second approved product, Lisaftoclax, is a Bcl-2 inhibitor for treating hematologic malignancies. The company is conducting several registrational Phase III trials for these products.
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) will report its 2025 six-month interim results and provide a corporate update on August 20, 2025. The company will host a Chinese language investor webcast at 9:00 pm EDT and an English language webcast at 8:00 am EDT on August 21, 2025.Ascentage Pharma is a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers. Its first approved product, Olverembatinib, is a third-generation BCR-ABL1 inhibitor, while its second approved product, Lisaftoclax, is a Bcl-2 inhibitor for treating hematologic malignancies. The company is conducting several registrational Phase III trials for these products, including POLARIS-2 for CML and GLORA for CLL/SLL [1].
The company’s management will participate in the Evercore China Biotech Summit from August 19 to 21, 2025, in Shanghai, China. They will engage in a fireside chat moderated by the Evercore ISI Research team and one-on-one investor meetings [2].
Ascentage Pharma has a robust R&D pipeline and strategic partnerships with leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent [1]. The company’s forward-looking statements include potential risks and uncertainties, such as those discussed in its filings with the SEC [1].
Investors are encouraged to tune in to the upcoming webcasts for the latest updates on Ascentage Pharma’s performance and future prospects.
References:
[1] https://www.biospace.com/press-releases/ascentage-pharma-to-participate-in-evercore-china-biotech-summit
[2] https://www.linknovate.com/news/ascentage-pharma-to-participate-in-evercore-china-biotech-summit-21067748/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet